Skip to main content

Table 1 Clinical characteristics and genomic profiling of PC GC and non-PC GC patients (N = 556)

From: FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

  No. of patients PC
n = 64 (%)
Non-PC
n = 492 (%)
Pb
Age (years) 556    0.004
 < 60 270 42 (65.6%) 228 (46.3%)  
 ≥ 60 286 22 (34.4%) 264 (53.7%)  
Gender 556    0.208
 Male 369 38 (59.4%) 331 (67.3%)  
 Female 187 26 (40.6%) 161 (32.7%)  
MSI status 545    0.085
 MSS 516 64 (100%) 452 (91.8%)  
 MSI-H 29 0 (0%) 29 (5.9%)  
TMBa 556    0.001
 TMB-L 411 58 (90.6%) 353 (71.7%)  
 TMB-H 145 6 (9.4%) 139 (28.3%)  
Gene SNVs and INDELs
 TP53 349 30 (46.9%) 319 (64.8%) 0.005
 CDH1 80 18 (28.1%) 62 (12.6%) 0.001
 ARID1A 98 9 (14%) 89 (18.1%) 0.426
 ERBB2 29 6 (9.4%) 23 (4.7%) 0.196
 CDKN2A 17 4 (6.3%) 13 (2.6%) 0.234
 RHOA 32 4 (6.3%) 28 (5.7%) 1.000
 SMAD4 33 2 (3.1%) 31 (6.3%) 0.465
Gene CNVs
 FGFR2 33 8 (12.5%) 25 (5.1%) 0.037
 CCNE1 63 2 (3.1%) 61 (12.4%) 0.028
 ERBB2 42 1 (1.6%) 41 (8.3%) 0.094
 VEGFA 28 1 (1.6%) 27 (5.5%) 0.295
Gene rearrangements
 FGFR2 8 2 (3.1%) 6 (1.2%) 0.518
  1. CNV copy number variations, INDEL short and long insertion/deletion, MSI microsatellite instability, MSI-H microsatellite instability-high, MSS microsatellite stable, PC poorly cohesive, SNV single nucleotide variant, TMB tumor mutation burden, TMB-H tumor mutational burden-high, TMB-L tumor mutational burden-low
  2. aTumors with TMB < 10 Muts/Mb are defined as TMB-L, while ≥ 10 Muts/Mb defined as TMB-H
  3. bPearson’s Chi-square test (or Fisher’s exact test) was used in statistical analyses. Values in italic are statistically significant